首页> Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology> Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

Effect of the mGluR5-NAM Basimglurant on Behavior in Adolescents and Adults with Fragile X Syndrome in a Randomized, Double-Blind, Placebo-Controlled Trial: FragXis Phase 2 Results.

导出 OA

翻译打印收藏纠错

第一作者： Eriene A,Youssef

第一单位： Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center New York, New York, NY, USA.

作者： Eriene A,Youssef ^[1] ; Elizabeth,Berry-Kravis ^[2] ; Christian,Czech ^[3] ; Randi J,Hagerman ^[4] ; David,Hessl ^[5] ; Chin Y,Wong ^[6] ; Michael,Rabbia ^[7] ; Dennis,Deptula ^[8] ; Amy,John ^[9] ; Russell,Kinch ^[10] ; Philip,Drewitt ^[11] ; Lothar,Lindemann ^[3] ; Moritz,Marcinowski ^[12] ; Rachel,Langland ^[13] ; Carsten,Horn ^[14] ; Paulo,Fontoura ^[15] ; Luca,Santarelli ^[16] ; Jorge A,Quiroz ^[17] ; FragXis Study Group

作者单位： Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center New York, New York, NY, USA. ^[1] Departments of Pediatrics, Neurological Sciences, and Biochemistry, Rush University Medical Center, Chicago, IL, USA. ^[2] Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Basel, Basel, Switzerland. ^[3] Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Department of Pediatrics, University of California Davis, School of Medicine, Sacramento, CA, USA. ^[4] Medical Investigation of Neurodevelopmental Disorders (MIND) Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis, School of Medicine, Sacramento, CA, USA. ^[5] Genentech Research and Early Development, South San Francisco, CA, USA. ^[6] Roche Product Development, Roche Innovation Center New York, New York, NY, USA. ^[7] ImmunoBrain Check Ltd., Ness-Ziona, Israel. ^[8] Gilead Sciences, Foster City, CA, USA. ^[9] Eisai EMEA, Hatfield, UK. ^[10] Roche Pharmaceutical Research and Early Development, Neuroscience, Ophthalmology, and Rare Diseases, Roche Innovation Center Welwyn, Welwyn, UK. ^[11] Roche Diagnostics GmbH, Mannheim, Germany. ^[12] Genomics & Oncology Research, Roche Molecular Systems, Inc., Pleasanton, CA, USA. ^[13] Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland. ^[14] Roche Neuroscience Product Development, Basel, Switzerland. ^[15] Therachon, AG, Basel, Switzerland. ^[16] Solid Biosciences, Cambridge, MA, USA. ^[17]